L. Ryan

发表

Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.

R. Shemin, T. Herman, J. Corson, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction

L. Weiner, L. Coia, S. Keller, 1998, Cancer.

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

J. Manola, M. Hanna, M. Oken, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.

J. Edmonson, S. Frytak, D. Parkinson, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Factors for Survival in Hepatocellular Carcinoma1

A. Cnaan, A. Schutt, G. Falkson, 2006 .

Prognostic factors for survival in hepatocellular carcinoma.

A. Cnaan, A. Schutt, G. Falkson, 1988, Cancer research.

Phase II Trial for the Evaluation of Trimetrexate in Patients with Inoperable Squamous Carcinoma of the Esophagus

D. Haller, G. Falkson, L. Ryan, 1992, American journal of clinical oncology.

Survival implications of enucleation after definitive radiotherapy for choroidal melanoma: an example of regression on time-dependent covariates.

E. Gragoudas, K. Egan, L. Ryan, 1998, Archives of ophthalmology.

Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.

D. Haller, D. Tormey, T. Anderson, 1996, Journal of the National Cancer Institute.

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282

D. Haller, J. Dutcher, A. Schutt, 1999, Medical oncology.

Phase II Trials of Interferons-α and -β in Advanced Sarcomas

E. Borden, R. Hahn, D. Tormey, 1992 .

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.

M. Socinski, S. Cannistra, J. Griffin, 1988, The New England journal of medicine.

Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.

J. Manola, S. Arbuck, A. Benson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.

A. Elias, J. Aisner, K. Antman, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797)

J. Edmonson, S. Okuno, D. Priebat, 2003, Cancer.

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

M. Buyse, J. Pignon, P. Rougier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

M. Buyse, J. Pignon, P. Rougier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.

A. Elias, H. Grier, K. Antman, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis.

E. Borden, D. Albert, L. Ryan, 1996, Archives of ophthalmology.

Prognostic factors in metastatic melanoma

E. Borden, A. Kramar, L. Ryan, 1993, Cancer.

Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.

A. Elias, K. Antman, L. Ryan, 1990, Seminars in oncology.

Phase II trials of interferons-alpha and -beta in advanced sarcomas.

E. Borden, R. Hahn, D. Tormey, 1992, Journal of Interferon Research.

Adults with Ewing's Sarcoma: An Analysis of 16 Patients at the Dana‐Farber Cancer Institute

K. Antman, R. Siegel, L. Ryan, 1988, American journal of clinical oncology.

Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group.

J. Kirkwood, T. Smith, D. Haller, 1998, International journal of radiation oncology, biology, physics.

A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study

P. Carbone, I. Simson, A. Schutt, 1987, Cancer.

Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group

J. Edmonson, C. Falkson, R. Blum, 2003, Sarcoma.

Morphology and other prognostic factors of hepatocellular carcinoma.

G. Falkson, Y. Dayal, A. Chedid, 1999, Archives of pathology & laboratory medicine.

Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.

G. Corner, L. Augenlicht, L. Augenlicht, 1997, Cancer research.

Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.

A. Elias, J. Aisner, K. Antman, 1990, Seminars in oncology.

Phase II Study of Aminothiadiazole in Advanced Squamous Cell Carcinoma of the Esophagus

D. Haller, P. Engstrom, G. Falkson, 1991, American journal of clinical oncology.